Ask AI

Search

Updates

Loading...

Table of contents

Urea cycle disorders

Background

Overview

Definition
UCDs are a group of rare inborn metabolic errors caused by deficiencies in enzymes or transporters of the urea cycle, leading to the accumulation of ammonia and other toxic metabolites in the body. These disorders include deficenies of N-acetylglutamate synthase, carbamoylphosphate synthetase 1, ornithine transcarbamylase, arginosuccinate synthetase (citrullinemia type 1), argininosuccinate lyase (argininosuccinic aciduria), arginase, ornithine translocase (hyperornithinemia-hyperammonemia-homocitrullinuria syndrome), and citrin (citrullinemia type 2).
1
2
Pathophysiology
The urea cycle is the primary pathway for converting excess nitrogen, in the form of ammonia, into urea for excretion. Deficiencies in specific enzymes or transporters disrupt this cycle, leading to the accumulation of ammonia (with a normal anion gap and normal blood glucose) and other metabolites (such as glutamine, alanine, and asparagine). Hyperammonemia disrupts potassium homeostasis and water transport in the brain, resulting in cytotoxic cerebral edema.
3
4
Epidemiology
The incidence of UCDs in the US is estimated at 1 per 35,000 births.
5
Disease course
Complete enzyme or transporter deficiencies typically present with severe hyperammonemia within the first week of life, causing symptoms such as vomiting, poor feeding, lethargy, hypothermia, and coma. Partial deficiencies usually present later in life with milder symptoms, including protein aversion, food refusal, frequent vomiting, poor appetite, and adverse reactions to high-protein foods. Hyperammonemic episodes may be triggered by infections, high protein intake, certain drugs, or other stressors, leading to acute metabolic decompensation.
2
Prognosis and risk of recurrence
The prognosis of UCDs varies according to the specific disorder, the severity of enzyme deficiency, and the timing of diagnosis and intervention. Early detection through newborn screening and prompt management can improve outcomes and reduce the risk of severe neurological damage. Fatality during the first hyperammonemic episode in neonatal-onset UCDs has been reported at 27%, but it is declining with the widespread use of RRT.
6
7

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of urea cycle disorders are prepared by our editorial team based on guidelines from the Nature Reviews Nephrology (NRN 2020), the Trans-European Working Group on Urea Cycle Disorders (TEWG-UCD 2019), and the European registry and network for Intoxication type Metabolic Diseases (E-IMD 2014).
1
2
3
4
5
6
7
8
9

Screening and diagnosis

Indications for screening: as per TEWG-UCD 2019 guidelines, consider obtaining newborn screening for early diagnosis of argininosuccinate synthetase deficiency and argininosuccinate lyase deficiency.
C
Show 2 more
Create free account

More topics in this section

  • Diagnosis

Diagnostic investigations

Initial laboratory tests: as per TEWG-UCD 2019 guidelines, measure ammonia levels as an emergency testing in patients with any acute or intermittent neurological deterioration or psychiatric illness, ALF, suspected intoxication, or neonatal sepsis, taking into account pre-analytical pitfalls.
A
Show 2 more

More topics in this section

  • Genetic testing

  • Enzyme analysis

Medical management

General principles: as per TEWG-UCD 2019 guidelines, initiate treatment in patients with hyperammonemia while awaiting the results of analysis of amino acids and acylcarnitines. Commence immediate measures to reserve endogenous protein catabolism and to promote ammonia detoxification.
B

More topics in this section

  • High-dose glucose and lipids

  • Nitrogen scavengers

  • N-carbamylglutamate

Nonpharmacologic interventions

Dietary management: as per TEWG-UCD 2019 guidelines, recognize that deficiencies of energy and/or essential amino acid and other nutrients can cause metabolic instability and morbidity. Involve a specialist metabolic dietitian to balance nutritional requirements with metabolic stability, following the FAO/WHO/UNU guidelines for protein and energy requirements.
B
Show 6 more

Therapeutic procedures

Extracorporeal detoxification, indications
As per TEWG-UCD 2019 guidelines:
Initiate extracorporeal detoxification in patients with severe neurological symptoms induced by hyperammonemia, in conjunction with medical treatment. Initiate extracorporeal detoxification as soon as possible unless initial medical treatment has already led to sufficient improvement of ammonia levels and the clinical situation.
B
Consider initiating extracorporeal detoxification as first-line treatment in adult patients with acute hyperammonemic decompensations.
C

More topics in this section

  • Extracorporeal detoxification (hemodialysis and hemodiafiltration)

  • Extracorporeal detoxification (peritoneal dialysis)

  • Extracorporeal detoxification (plasma exchange)

  • Extracorporeal detoxification (hybrid therapy)

Surgical interventions

Liver transplantation: as per TEWG-UCD 2019 guidelines, consider offering liver transplantation in patients with severe UCDs without sufficient response to standard treatment and with poor QoL, without severe neurological damage and ideally while in a stable metabolic condition.
C
Show 2 more

More topics in this section

  • Considerations for elective surgeries

Specific circumstances

Pregnant patients: as per TEWG-UCD 2019 guidelines, continue treatment with nitrogen scavengers in pregnant patients with UCDs. Consider administering sodium benzoate based on biochemical mechanisms.
B
Show 4 more

Patient education

General counseling: as per TEWG-UCD 2019 guidelines, consider providing written medication treatment sheets to parents, pharmacists, and persons involved in patient care.
C

Preventative measures

Routine immunizations: as per TEWG-UCD 2019 guidelines, offer vaccinations in patients with UCDs following national schedules.
B

Follow-up and surveillance

Follow-up: as per TEWG-UCD 2019 guidelines, obtain regular clinical, biochemical, and nutritional monitoring in all patients with UCDs by a multidisciplinary metabolic team following individualized schedules.
E
Show 4 more